Literature DB >> 7772538

alpha-Interferon therapy for congenital dyserythropoiesis type I.

T Lavabre-Bertrand1, P Blanc, R Navarro, M Saghroun, H Vannereau, M Braun, A Wagner, J Taïb, C Lavabre-Bertrand, M Navarro.   

Abstract

We report the case of a 28-year-old female followed for congenital dyserythropoiesis type I which required repeated transfusions. Alpha-2a interferon treatment was started because of post-transfusion chronic viral hepatitis type C. Following this treatment, haemoglobin level increased and reached normal value during the 24 weeks of interferon treatment. When interferon therapy was stopped, haemoglobin level returned to previous values, requiring more transfusions. Resumption of interferon therapy resulted again in a complete normalization of haemoglobin level. Erythrokinetic studies demonstrated a striking reduction of the ineffective erythropoiesis, and electron microscopy study a reduction in nuclear structure abnormalities. To our knowledge, this is the first report of the efficacy of interferon in congenital dyserythropoiesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7772538     DOI: 10.1111/j.1365-2141.1995.tb08442.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon Alpha.

Authors:  Ayse Salihoglu; Tugrul Elverdi; Ahmet Emre Eskazan; Deniz Eyice; Isil Bavunoglu; Muhlis Cem Ar; Seniz Ongoren; Elif Guzel; Zafer Baslar; Aydin Tunckale; Nukhet Tuzuner; Teoman Soysal
Journal:  Indian J Hematol Blood Transfus       Date:  2015-09-21       Impact factor: 0.900

2.  Congenital dyserythropoietic anemia type I is caused by mutations in codanin-1.

Authors:  Orly Dgany; Nili Avidan; Jean Delaunay; Tatyana Krasnov; Lea Shalmon; Hanna Shalev; Tal Eidelitz-Markus; Joseph Kapelushnik; Daniel Cattan; Alexandre Pariente; Michel Tulliez; Aurore Crétien; Pierre-Olivier Schischmanoff; Achille Iolascon; Eithan Fibach; Ariel Koren; Jochen Rössler; Martine Le Merrer; Isaac Yaniv; Rina Zaizov; Edna Ben-Asher; Tsvyia Olender; Doron Lancet; Jacques S Beckmann; Hannah Tamary
Journal:  Am J Hum Genet       Date:  2002-11-14       Impact factor: 11.025

3.  Congenital dyserythropoietic anemia.

Authors:  Takahiro Kamiya; Atsushi Manabe
Journal:  Int J Hematol       Date:  2010-09-07       Impact factor: 2.490

Review 4.  The congenital dyserythropoieitic anemias: genetics and pathophysiology.

Authors:  Richard King; Patrick J Gallagher; Rami Khoriaty
Journal:  Curr Opin Hematol       Date:  2021-12-24       Impact factor: 3.218

5.  Response to Alpha-Interferon Treatment of the Congenital Dyserythropoietic Anemia type I in Two Sicilian Beta Thalassemia Carriers.

Authors:  V Agrigento; R Barone; S Sclafani; R Di Maggio; M Sacco; A Maggio; E D'Alcamo
Journal:  Indian J Hematol Blood Transfus       Date:  2016-12-18       Impact factor: 0.900

6.  Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR).

Authors:  Omar Niss; Robert B Lorsbach; Mikaela Berger; Satheesh Chonat; Morgan McLemore; David Buchbinder; Timothy McCavit; Linda G Shaffer; Jessica Simpson; Jeffrey H Schwartz; Jessica Meznarich; Myesa Emberesh; Katie G Seu; Wenying Zhang; Theodosia A Kalfa
Journal:  Blood Cells Mol Dis       Date:  2020-12-24       Impact factor: 3.039

Review 7.  The pathogenesis, diagnosis and management of congenital dyserythropoietic anaemia type I.

Authors:  Noémi B A Roy; Christian Babbs
Journal:  Br J Haematol       Date:  2019-03-05       Impact factor: 6.998

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.